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Background. To replicate, lentiviruses such as HIV must integrate DNA copies of their RNA genomes into host cell
chromosomes. Lentiviral integration is favored in active transcription units, which allows efficient viral gene expression after
integration, but the mechanisms directing integration targeting are incompletely understood. A cellular protein, PSIP1/LEDGF/
p75, binds tightly to the lentiviral-encoded integrase protein (IN), and has been reported to be important for HIV infectivity
and integration targeting. Methodology. Here we report studies of lentiviral integration targeting in 1) human cells with
intensified RNAi knockdowns of PSIP1/LEDGF/p75, and 2) murine cells with homozygous gene trap mutations in the PSIP1/
LEDGF/p75 locus. Infections with vectors derived from equine infections anemia virus (EIAV) and HIV were compared.
Integration acceptor sites were analyzed by DNA bar coding and pyrosequencing. Conclusions/Significance. In both PSIP1/
LEDGF/p75-depleted cell lines, reductions were seen in lentiviral infectivity compared to controls. For the human cells,
integration was reduced in transcription units in the knockdowns, and this reduction was greater than in our previous studies
of human cells less completely depleted for PSIP1/LEDGF/p75. For the homozygous mutant mouse cells, similar reductions in
integration in transcription units were seen, paralleling a previous study of a different mutant mouse line. Integration did not
become random, however–integration in transcription units in both cell types was still favored, though to a reduced degree.
New trends also appeared, including favored integration near CpG islands. In addition, we carried out a bioinformatic study of
15 HIV integration site data sets in different cell types, which showed that the frequency of integration in transcription units
was correlated with the cell-type specific levels of PSIP1/LEDGF/p75 expression.
Citation: Marshall HM, Ronen K, Berry C, Llano M, Sutherland H, et al (2007) Role of PSIP1/LEDGF/p75 in Lentiviral Infectivity and Integration
Targeting. PLoS ONE 2(12): e1340. doi:10.1371/journal.pone.0001340
INTRODUCTION
Early steps of retroviral replication involve reverse transcription to
generate a DNA copy of the viral RNA genome, and integration,
which results in the covalent connection of the viral DNA to host
cell DNA (for reviews see [1,2]). The question of where
retroviruses target DNA integration is central to understanding
viral host interactions. For the virus, selection of favorable sites for
viral DNA integration assists efficient expression of the viral
genome after integration [3–6]. For the host, viral DNA
integration can either activate or inactivate gene transcription.
One consequence of integration can be insertional activation of
oncogenes and transformation to malignant growth [1,2,7,8].
Here we present data on the role of a host-cell encoded protein,
PSIP1/LEDGF/p75, that guides integration site selection by
lentiviruses, the viral genus including HIV (henceforth we use
‘‘LEDGF/p75’’ because this name is widely used in the HIV field).
LEDGF/p75 first came to the attention of the retrovirus field
when it was identified in affinity-based screens for its tight binding
to HIV IN [9–11]. LEDGF/p75 tethers ectopically-expressed
HIV IN to chromatin [9,10,12,13], through specific binding
domains [14–17], and also protects IN from proteasomal
degradation [18]. LEDGF/p75 binding is specific for lentiviral
IN proteins (e. g. those of HIV, SIV, FIV, and EIAV)[12,19,20],
which makes it appealing as a candidate tethering factor since all
the lentiviruses tested (HIV, SIV, FIV, and EIAV) show favored
integration in active transcription units [5,21–32]. The crystal
structure of the catalytic domain of HIV IN (residues 50–212)
bound to the integrase binding domain (IBD) was solved, which
showed that a pair of LEDGF/p75-IBD molecules could bind at
symmetry-related positions at the interface of the IN catalytic
domain dimer [33,34]
Early attempts to determine whether LEDGF/p75 was
important for efficient HIV replication used RNAi knockdowns
in human cells, which had either no effect or quantitatively modest
effects on infection [12,13,35,36]. This now appears to be because
incomplete knockdowns left biologically significant amounts of
protein present. More recently, human SupT1 cells with
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1340intensified RNAi knockdowns showed drops of 30-fold for
infection by either HIV or another lentivirus, feline immunode-
ficiency virus (FIV), and combining this with dominant interfering
proteins derived from the LEDGF/p75-IBD produced 560-fold
inhibition of infection [37]. These findings are supported by
additional studies in human cell lines [35,38,39].
Early knockdowns of LEDGF/p75 were also analyzed for
effects on targeting of HIV integration [40]. Knockdowns in three
cell types were studied, and in each integration frequency within
transcription units was reduced. In addition, other effects were
seen, including an increase in the content of G/C bases around
sites of HIV integration in the knockdown cells. These data
supported the idea that LEDGF/p75 acted as a tethering factor,
binding to both HIV and chromatin to direct HIV integration into
active genes. In support of the tethering model, artificial fusion
proteins in which the LEDGF/p75 IBD was fused to the sequence
specific DNA binding domain of phage lambda repressor were
shown to direct favored integration in vitro near repressor binding
sites [24]. Also supporting the tethering idea, function of LEDGF/
p75 in promoting HIV replication requires that both ends of the
putative LEDGF/p75 tether be intact [37].
However, key questions still remain on the role of LEDGF/p75.
In all the models studied, HIV continued to favor integration
within active transcription units. This could either be because
residual LEDGF/p75 remaining in the knockdown was sufficient
for residual targeting activity, or because additional host cell
factors also contribute independently to targeting HIV integration.
In an effort to address this issue, Shun et al. prepared a mouse
strain in which part of the LEDGF/p75 locus was flanked by Cre
recombination sites [41], and the LEDGF/p75 exon was deleted by
exposure to Cre recombinase. Mouse embryonic fibroblasts were
then studied for effects on infection with HIV reporter viruses.
These cells showed a 20-fold reduction in infectivity by HIV, and
also a reduction in integration frequency in transcription units that
was stronger than that reported in human cell knockdowns by
Ciuffi et al. [40]. However, HIV did still infect at a reduced rate,
and integration in transcription units was still significantly favored.
The mouse cells also showed some new targeting features in the
LEDGF/p75-depleted cells, including increased integration near
CpG islands.
These studies were helpful in clarifying the effects of strong
LEDGF/p75 depletion, but several issues remain. We wished to
obtain lentiviral integration targeting data for human cells with
stronger knockdowns of LEDGF/p75 to investigate possible effects
of the host cell species. We also wished to obtained data from an
additional murine cell line depleted for LEDGF/p75 to check the
generality of conclusions from Shun et al. [41]. We thus studied
the human SupT1 T-cell line with intensified RNAi developed by
Llano et al. [37], and mouse cells containing homozygous gene
trap mutations at the LEDGF/p75 locus developed by Sutherland
and coworkers [42]. Vectors derived from equine infectious
anemia virus (EIAV) were used in many of the experiments,
allowing effects on HIV and EIAV to be compared. Studies of
both cell models and both lentiviruses provided strong evidence for
the role of LEDGF/p75 in promoting efficient infection and
targeting integration in transcription units. In addition to these
data on manipulated cell models, we also present additional
bioinformatic studies of 15 published HIV integration site data sets
in different cell types, which revealed a strong correlation between
cell type specific LEDGF/p75 expression levels and the proportion
of HIV integration sites in transcription units. These data provide
further support for the generality of LEDGF/p75 as a determinant
of integration target site selection for lentiviruses in primary cells
where LEDGF/p75 levels were not artificially reduced.
RESULTS
Efficiency of lentivirus infection in human SupT1
cells with intensified knockdown of LEDGF/p75
Initially cells depleted for LEDGF/p75 were tested for effects on
lentiviral infection. For the human SupT1 cells with the intensified
LEDGF/p75 knockdown (the TC2 and TL2 cell lines in [37]),
there were technical complications in studying HIV integration
targeting. To generate the cells, shRNAs were introduced using
HIV-based vectors. Thus the modified cells already contain
integrated HIV sequences, which would complicate sequence
analysis of newly integrated HIV proviruses. For that reason, we
studied the lentivirus equine infectious anemia virus (EIAV). Like
HIV IN, EIAV IN is known to bind LEDGF/p75 [20], and EIAV
is also known to integrate in active transcription units [31], so
EIAV is a suitable model for analysis of the influence of LEDGF/
p75 on lentivirus infection.
Figure 1 shows the efficiency of infection by HIV and EIAV in
the modified SupT1 cells. HIV infection efficiency was character-
ized two days after infection using a luciferase-transducing HIV
vector. Activity was compared for unmodified SupT1 cells or
control cells containing a scrambled shRNA sequence (SCRAM).
Luciferase activity was reduced ,10 fold in the LEDGF/p75
knockdown but not in the control cells, and similar effects were
seen at two multiplicities of infection (Figure 1A and B), paralleling
previously published data from Llano et al. [37].
An EIAV vector was also tested (Figure 1C and D). Infection
through the step of integration was monitored by infecting cells,
then growing the cells for two weeks, so that only covalently
integrated DNA persisted (unintegrated DNA is degraded or lost
by dilution during prolonged cell growth [43,44]). EIAV DNA was
then quantified in genomic DNA samples using quantitative PCR.
The LEDGF/p75 knockdown cells showed only between 8 and
24% of the amount of viral DNA seen in the control cells,
indicating that for EIAV as well LEDGF/p75 is important for
completing the early steps of replication.
Efficiency of lentivirus infection in murine cells
disrupted at LEDGF/p75
We also compared lentiviral infection in murine cells containing the
gene trap disruption of LEDGF/p75 reported by Sutherland and
colleagues [42]. Because residual expression is sometimes detected in
gene trap alleles, we used quantitative RT-PCR to determine the
fraction of LEDGF/p75 messages disrupted by the gene trap
insertion. In samples from homozygous mutant (2/2)c e l l s ,
amplification of correct LEDGF/p75 message was sporadically
detected at high PCR cycle numbers, suggesting that rare correctly
spliced messages were formed. However, quantification of correct
message formation using SyberGreen quantitative PCR showed
expression of LEDGF/p75 to be below the limit of detection in the
2/2cells,correspondingtoa reductionofat least32-fold compared
to the wild type (+/+) cells (unpublished data). Sutherland and
coworkers reported LEDGF/p75 protein to be undetectable [42].
We analyzed infection of murine embryonic fibroblasts (MEFs)
isolated from embryos of +/+ and homozygous mutant 2/2 mice
after infection with HIV and EIAV. Integration was measured by
infecting cells, maintaining the cells in culture for two weeks to
allow loss of unintegrated DNA [44], then quantifying the viral
DNA by TaqMan PCR. HIV integration was reduced ,five fold
in the LEDGF/p75 2/2 MEFs (Figure 2A), and EIAV integration
was reduced .50 fold. Thus in the presence of a homozygous
mutation of LEDGF/p75, lentiviral integration was strongly
reduced but not eliminated.
LEDGF in Lentiviral Infection
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integration site placement
Below we first describe studies of EIAV integration targeting in the
SupT1 cells with intensified RNAi knockdowns, then HIV and
EIAV targeting in the mouse cells disrupted at LEDGF/p75.
For each of our studies, we used the pyrosequencing technology
commercialized by 454 Life Sciences [45] to sequence genomic
DNA flanking integrated proviruses. Briefly, genomic DNA was
isolated and cleaved with restriction enzymes. DNA linkers were
ligated onto the cleaved ends, then host-virus DNA junctions were
amplified using one primer complementary to the linker and one
complementary to the viral DNA end. A second round of PCR was
used to improve specificity and to add recognition sites for the 454
primers necessary for the emulsion PCR step preceding pyrosequen-
cing [46]. Pooled DNAs were then subjected to pyrosequencing.
Use of DNA bar coding allowed multiple integration site
populations to be studied in parallel [47–49]. The viral DNA
primer used in the second round of amplification contained a short
recognition sequence (4–8 bases) abutting the 454 primer that was
different for each sample tested. These 4–8 bases are the first
determined inpyrosequencing reads.Thususeofbarcodingallowed
many samples to be pooled for sequence determination, then the
reads could be sorted into individual experiments by bar code. A
total of 3566 unique integration site sequences from different virus
and cell combinations were determined using this method (Table 1).
Consensus sequences at EIAV integration sites in
human SupT1 cells
The EIAV vector was used to infect SupT1 cells with intensified
RNAi against LEDGF/p75 and compared to controls consisting of
either SupT1 cells with a scrambled shRNA (SCRAM) or
untreated SupT1 cells. Integration sites were sequenced and
placed on the hg18 draft human genome sequence. As a first step
in the analysis, the favored target DNA sequences at the point of
integration were compared in the presence and absence of
LEDGF/p75. Alignment of target DNA sequences at integration
sites has revealed weak inverted repeat consensus sequences [50–
55], the symmetry arising because the favored sequence features at
each of the two viral DNA ends are the same. The presence of this
consensus sequence can be a strong predictor of integration
targeting specificity, particularly over short intervals [55]. For
HIV, the favored consensus sequence has been synthesized and
shown to be a favored integration target site for HIV preintegra-
tion complexes in vitro [52].
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Figure 1. Effects of intensified knockdown of LEDGF/p75 in SupT1 cells on the efficiency of lentiviral infection. A) and B) HIV luc activity was
compared for wild-type SupT1 cells, SupT1 containing a control scrambled shRNA (SCRAM), and LEDGF/p75 knockdown (KD) cells. A) High
multiplicity of infection (80 ng p24); B) Lower multiplicity of infection (20 ng p24). The designation ‘‘p24’’ indicates the amount of viral stock,
measured by the weight of the p24 capsid antigen applied to cells. C) and D) EIAV infectivity was compared in the SupT1 cell set as assayed by
quantitative PCR for viral cDNA: C) high multiplicity (100 ml stock), D) lower multiplicity (25 ml stock).
doi:10.1371/journal.pone.0001340.g001
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1340EIAV has been reported to favor integration in an A/T rich
palindromic consensus sequence [31], which matched that seen
here for EIAV integration in the control SupT1 and SupT1
SCRAM cell lines (Figure 3A and B). The LEDGF/p75
knockdown cells showed an indistinguishable consensus sequence
(Figure 3C), providing evidence against the view that LEDGF/p75
is involved in specifying the target sequence preference.
EIAV integration targeting in human SupT1 cells
depleted for LEDGF/p75
The genomic distribution of EIAV integration sites was then
compared in the presence and absence of LEDGF/p75 (Table 2
and Figure 4). Integration site data sets were compared
systematically relative to many forms of genomic annotation.
Complete reports are in Statistical Reports S1 and S2. Major
findings are summarized below.
Three catalogs of human gene annotation were used to analyze
EIAV integration site distributions, since LEDGF/p75 had
previously been implicated in directing HIV integration to
transcription units. From 60 to 69% of EIAV integration sites were
in genes (Table 2), while a computationally generated random
distribution showed only 37 to 43 % ingenes. In the cellline strongly
depleted for LEDGF/p75, integration frequency in genes ranged
from 45% to 52%, a significant reduction compared to the pooled
SupT1 and SupT1 SCRAM controls (P,0.0001 for Known genes,
P,0.0001 for RefSeq, P=0.027 for Unigenes; comparison to
pooled controls by the Fisher’s exact test). However, even in the
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Figure 2. Efficiency of lentiviral infection in control (+/+) and homozygous LEDGF/p75-disrupted (2/2) murine cells, measured by quantitative
PCR. A) HIV infectivity. B) EIAV infectivity.
doi:10.1371/journal.pone.0001340.g002
Table 1. Integration site data sets used in this study.
..................................................................................................................................................
Cell line Description and LEDGF/p75 status Virus
Number of
Integration Sites
Source of sequences
analyzed
SupT1 Human SupT1 cell line EIAV vector 783 This report
TC2 (SupT1 SCRAM) Human SupT1 cell line with ilvRNAi with scramble shRNA, polyclonal EIAV vector 869 This report
TL2 (SupT1 LEDGF KD) Human SupT1 cell line with ilvRNAi for LEDGF/p75, polyclonal EIAV vector 157 This report
Jurkat siJK2 Human Jurkat cell line, shRNA LEDGF/p75 knock down HIV vector 695 [37]
Jurkat-siJK2BC Human Jurkat cell line, shRNA LEDGF/p75 knock down back complimented
with p75/LEDGF insensitive to the shRNA
HIV vector 685 [37]
293T-siLL Human 293T cell line, with shRNA LEDGF knock down HIV vector 593 [37]
293T-siScram Human 293T cell line, with scramble shRNA HIV vector 450 [37]
iMEF +/+ Murine embryonic fibroblasts from wild-type mice (immortalized) HIV vector 574 This report
iMEF 2/2 Murine embryonic fibroblasts from knockout mice (immortalized) HIV vector 287 This report
prMEF +/+ Murine embryonic fibroblasts from wild-type mice (primary) HIV vector 531 This report
prMEF 2/2 Murine embryonic fibroblasts from knockout mice (primary) HIV vector 209 This report
iMEF +/+ Murine embryonic fibroblasts from wild-type mice (immortalized) EIAV vector 70 This report
iMEF 2/2 Murine embryonic fibroblasts from knockout mice (immortalized) EIAV vector 86 This report
doi:10.1371/journal.pone.0001340.t001
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PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1340absence of LEDGF/p75, integration in genes was still significantly
favored over random in two out of three sets of gene calls (Table 2).
Figure 4A shows the extent of favoring of integration in RefSeq
transcription units normalized to the random expectation.
In some data sets integration by lentiviruses has been found to
be disfavored near CpG islands [22], which are genomic regions
enriched in the rare CpG dinucleotide and commonly associated
with transcription start sites and regulatory regions. EIAV also
showed disfavored integration near CpG islands (P,0.0001 for
comparison random sites by the Fisher’s exact test). In the
LEDGF/p75-depleted cells, integration frequency within 2 Kb of
CpG islands went up, so that CpG islands were no longer
disfavored (Table 2), and the difference between pooled SupT1
control sites and LEDGF/p75-depleted cells achieved significance
(P,0.0001, Fisher’s exact test). Figure 4B shows the frequency
within 1 kb, plotted to emphasize the enrichment over random.
CpG islands are often associated with transcription start sites.
Analysis of integration frequency showed a trend toward more
frequent integration near transcription start sites in the knockdown
(6% in pooled SupT1 controls versus 10% in the knockdown)
though the trend did not achieve significance with this sample size
(P=0.083 by the Fisher’s exact test).
In the previous study of weaker LEDGF/p75-knockdowns [40],
HIV integration in knockdown cells was associated with an
increase in the relative G/C content at integration sites. One
speculation was that this was because LEDGF/p75 contains an A/
T hook DNA binding domain, which may promote integration in
A/T-rich regions in LEDGF/p75-positive cells [40]. Figure 4C
shows that in the SupT1 cell model as well, strong depletion of
LEDGF/p75 resulted in increased G/C content at integration
sites (P=0.0003 by regression analysis).
One of the main questions at the start of this study was whether
a stronger knockdown of LEDGF/p75 would result in stronger
effects on lentivirus integration targeting. Figure 5 shows a
comparison of two HIV integration site data sets from Ciuffi et
al. for HIV integration in Jurkat or 293T cells [40], which
harbored less complete knockdowns of LEDGF/p75. In the
control cells (Figure 5, blue shading) integration was enriched in
transcription units in all cases. In the LEDGF/p75 knockdowns
(Figure 5, orange and yellow shading), the proportion of
integration sites in genes was reduced, with the percent change
significantly greater in the intensified SupT1 knockdown over
many of the gene catalogs studied.
Integration frequency at some of the genomic features studied
was not detectably affected by the LEDGF/p75 knockdown. For
example, when integration frequency was assessed relative to gene
density, no strong effect was seen (Figure 4D). Similarly, the
relationship between gene activity and integration frequency was
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1340not significantly altered (Figure 4E). Integration frequency near
open chromatin as marked by DNAse I hypersensitive sites was also
not significantly altered by the knockdown (data not shown). This
implies that either there is residual LEDGF/p75 present even in the
intensified knockdownsthat issufficient toinfluence targeting, orelse
other cellular systems contribute to integration targeting as well.
Consensus sequences at lentiviral integration sites
in murine cells disrupted at LEDGF/p75
We analyzed integration sites in murine embryonic fibroblasts
(MEFs) derived from the LEDGF/p75 homozygous gene trap (2/
2) and control (+/+) mice [42] after infection with HIV and
EIAV. Cells that had been immortalized in culture (iMEF) were
compared to primary MEFs (prMEFs). For all the features
discussed below the results were identical for iMEFs and prMEFs
(data not shown), so the two data sets were pooled in what follows.
Integration site sequences were aligned to determine the
consensus palindromic sequence at the point of integration, and
results were compared for the +/+ and 2/2 MEFs for each virus
(Figure 6). In both cases, integration in the +/+ MEFs showed the
weak consensus seen previously for HIV and EIAV. No major
differences were seen in the 2/2 MEFs, consistent with findings
described above for human cells and previously [40,41].
EIAV integration targeting in murine cells disrupted
at LEDGF/p75
Genome-wide studies of EIAV integration targeting in murine
cells are presented in this section and analysis of HIV integration
in murine cells is described in the next section. Extensive further
analysis of EIAV and HIV integration in MEFs is presented in
Statistical Reports S2.
EIAV integration in transcription units was decreased in the 2/
2 LEDGF/p75 gene trap cells compared with wild-type. In wild-
type cells, 58.6% of experimental integration sites were in RefSeq
genes (see Table 3), a significant enrichment over the 28% seen in
the matched random controls (see Figure 7A). In 2/2 MEFs,
38.4% of sites were in RefSeq transcription units, a value that is
significantly less than in the +/+ MEFs (p=0.016 by the Fisher’s
exact test). Significant differences were seen when the analysis was
repeated using other gene catalogs as well (Table 3).
We also analyzed the proximity of EIAV integration sites to
CpG islands (Figure 7B and Table 3). In wild-type cells integration
within 2 kb of CpG islands was not significantly different from
random, while in knockout cells integration was 13-fold enriched
over random (P=0.0086; Fisher’s exact test).
The frequency of integration within 5 kb of RefSeq gene 59
ends showed a similar pattern (Table 3). Integration levels around
gene 59 ends were not significantly different from random in the
+/+ cells (5.7% of sites), whereas in the knockout a significant
enrichment was observed (25.6% of sites) achieving P=0.014 for
the comparison between cell types (Fisher’s exact test).
We analyzed the correlation between integration frequency and
G/C content using a 5 kb window around the integration site. A
significant difference between genotypes was found (P=0.001,
using regression analysis, Figure 7C).
A variety of features analyzed did not show significant
differences between genotypes, including the response to gene
density (Figure 7D) and the relationship between gene activity and
integration frequency (Figure 7E). We return to the implications of
these findings in the Discussion.
HIV integration targeting in murine cells disrupted
at LEDGF/p75
Data on HIV integration site distributions in MEFs closely matched
the data for EIAV integration (Figure 8 and Table 3). HIV
integration in +/+MEFs showed a strong preference for transcription
units (Table 3 and Figure 8), which was strongly reduced in the 2/2
MEFs (P,0.0001 for comparison between genotypes).
HIV integration within 2 kb of CpG islands was found to be
disfavored compared with matched random controls, and this was
the case in +/+ MEFs (Figure 8B and Table 3). Integration in 2/
2 MEFs was greatly increased within 2 kb of CpG islands or 5 kb
of transcription start sites (P,0.0001 and P=0.014 or the
respective comparisons between genotypes).
Knockdown of LEDGF/p75 has previously been shown to
result in an increase in the G/C content of HIV integration site
sequences [40]. We therefore analyzed the frequency of integra-
tion in regions of varying G/C content (Figure 8C), revealing that
integration was significantly increased in more G/C rich regions in
the 2/2 MEFs (P=4e-16).
As seen above for EIAV, the frequency of integration near a
variety of features was not detectably altered. Figure 8D shows
that integration frequency was similarly favored in gene-rich
regions in both the +/+ and 2/2 MEFs. Figure 8E shows that the
relative activity of genes hosting integration events was also not
distinguishable for the +/+ and 2/2 MEFs (Figure 8E).
Correlation between LEDGF/p75 expression and the
frequency of HIV integration in transcription units
analyzed over many cell types
Inaddition tostudying cellswithartificiallyreduced levelsofLEDGF/
p75 expression, we were interested in natural variation in cellular
LEDGF/p75 expression levels. Different primary cell types and cell
Table 2. Integration frequency in the presence and absence of LEDGF/p75 near mapped genomic features in the human genome.
..................................................................................................................................................
Frequency in Genomic Feature (%)
Transcription Units
Data Set Known RefSeq Unigenes ,2 kb CpG Island ,5 kb Gene 59 End
EIAV in SupT1 66.5*** 60.3*** 59.6*** 0.64** 6.5
EIAV in TC2 (SCRAM) SupT1 69.4*** 61.8*** 61.9*** 0.92** 5.4
EIAV in TL2 (LEDGF KD) SupT1 50.3 44.6* 51.6* 5.7 9.6
Random Control 43.3 36.5 42.2 2.4 5.6
Significant deviation from matched random controls according to the Fisher’s exact test is denoted by * (***p,0.0001, **p,0.01, *p,0.05). The ‘random control’ set is
the matched random control set for the SupT1 integration set (see Materials and Methods for generation of matched random controls).
doi:10.1371/journal.pone.0001340.t002
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1340lines show different steady state levels of LEDGF/p75 mRNA.
Different cell types also show reproducibly different frequencies of
HIV integration in transcription units (see [40] for examples). We
thus asked whether cell types with higher LEDGF/p75 levels showed
higher frequencies of HIV integration transcription units.
We analyzed data from 15 HIV integration site data sets for
which we also had transcriptional profiling data on gene activity
for that cell type. For each microarray data set, the expression level
of LEDGF/p75-specific probe sets was ranked relative to all other
probe sets on the array for that cell type, thus yielding a value for
relative LEDGF/p75 expression. These values were then plotted
against the proportion of HIV integration sites in transcription
units for that cell type (Figure 9). This analysis showed that
increased relative LEDGF/p75 mRNA abundance positively
correlated with increased HIV integration frequency in transcrip-
tion units (R
2=0.61; P,0.0001). Figure 9 shows data with
experimental LEDGF/p75 knockdowns included (triangles), but
the correlation was still significant when the experimental
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1340knockdowns were excluded (P,0.0001), indicating that natural
variation in LEDGF/p75 levels was functionally significant.
Some of the data in Figure 9 and in previous studies was
generated using transformed cell lines, leaving open the question
of whether natural variation in LEDGF/p75 levels was function-
ally important in human primary cells. We repeated the analysis in
Figure 9 using only data from human primary cells where
LEDGF/p75 levels had not been altered experimentally, and
again found a significant positive correlation between integration
frequency in genes and LEDGF/p75 mRNA levels (P=0.044).
These data indicate that natural variation in LEDGF/p75
expression levels is a significant determinant of integration
frequency in transcription units in human primary cells.
DISCUSSION
Here we report studies of lentiviral integration in two cell types
with strong depletions of LEDGF/p75. In the first, we studied the
SupT1 human T-cell line with intensified RNAi against LEDGF/
p75 described in [37]. Extensive characterization has shown that
these cells have stronger knockdowns than those studied previously
(e. g. [12,40]), providing an improved model for the role of
LEDGF/p75 in lentiviral integration targeting in human T-cells.
In the second cell model, we studied murine cells with a
homozygous gene-trap mutation disrupting the LEDGF/p75 locus
[42]. We also presented data on EIAV, extending the collection of
lentiviruses shown functionally to be affected by LEDGF/p75.
Infectivity for both HIV and EIAV was reduced 5–50 fold in
LEDGF/p75-depleted cells, in good agreement with data on HIV
and FIV published previously [37,41]–taken together, these studies
firmly establishing that strong LEDGF-p75 knockdowns strongly
reduce HIV infectivity. The data reported on target site selection
in human cells and murine cells were closely parallel with each
other, and also parallel with studies of another murine LEDGF/
p75 mutant [37,41]. Comparison of integration targeting data
reported here to earlier data with weaker knockdowns [40] showed
that indeed intensifying the LEDGF/p75 depletion further
diminished the proportion of lentiviral integration sites in
transcription units. Because more than half of the favoring of
transcription units was eliminated by the stronger depletion of
LEDGF/p75, we can conclude that the LEDGF/p75-dependent
pathway is the predominant pathway for targeting integration to
transcription units.
Published studies of integration targeting by LEDGF/p75 have
relied on analysis of cells where the LEDGF/p75 levels were
artificially reduced—thus there is interest in obtaining data on the
effects of LEDGF/p75 in cells naturally expressing different levels
of the protein. We took advantage of the observation that different
cell types differ reproducibly in their frequency of integration in
transcription units [40] to investigate this question. A bioinfor-
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PLoS ONE | www.plosone.org 8 December 2007 | Issue 12 | e1340matic comparison (Figure 9) showed that higher levels of LEDGF/
p75 expression correlated with higher frequencies of integration in
transcription units. The trend achieved significance even when the
analysis was restricted to human primary cells only. Thus the study
of natural variation in LEDGF/p75 expression allowed us to
extend the idea that LEDGF/p75 directs HIV integration to
transcription units in human primary cells without artificially
reduced LEDGF/p75 levels.
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Table 3. Integration frequency in the presence and absence of LEDGF/p75 near mapped genomic features in the murine genome.
..................................................................................................................................................
Frequency in Genomic Feature (%)
Transcription Units
Data Set Known RefSeq Ensemble ,2 kb CpG Island ,5 kb Gene 59 End
HIV in +/+ MEF 58.6*** 54.3*** 60.7*** 0.7* 10.9***
HIV in 2/2 MEF 42.9*** 38.7*** 46.0*** 6.5*** 15.5***
EIAV in +/+ MEF 62.9*** 58.6*** 64.3*** 1.4 5.7
EIAV in 2/2 MEF 41.9 38.4 45.3 12.8*** 25.6***
Random Control 29.7 28 32 1.7 6.8
Significant deviation from matched random controls according to the Fisher’s exact test is denoted by * (***p,0.0001, **p,0.01, *p,0.05). The ‘random control’ set
shown is the matched random control set for the HIV +/+ integration set (see Materials and Methods for generation of matched random controls).
doi:10.1371/journal.pone.0001340.t003
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PLoS ONE | www.plosone.org 9 December 2007 | Issue 12 | e1340A simple model holds that LEDGF/p75 directs favored
integration into transcription units by tethering. According to this
model, one domain of LEDGF/p75 binds to HIV preintegration
complexes and the other binds chromatin at active transcription
units. Data from artificial tethering studies in vitro with fusions of
the LEDGF/p75 IBD to a sequence-specific binding domain
support this model [56]. The tethering model predicts that
LEDGF/p75 should accumulate on active transcription units, but
so far this has not been demonstrated experimentally. Similarly, it
is not known how LEDGF/p75 recognizes active transcription
units. One possible model would be that histone post-translational
modifications mark active transcription units and guide LEDGF/
p75 binding. Potentially consistent with this idea is the finding that
HIV integration is positively correlated with several types of
histone post-translational modifications [46].
Curiously, both this study and Shun et al. [41] showed not only
a loss of integration targeting in LEDGF/p75-depleted cells, but
new favored genomic regions as well. From the previous study
alone this might have been an idiosyncrasy of the murine model,
but data presented here shows a similar response in human cells.
In all LEDGF/p75-depleted cell types in both studies, integration
became more favored near transcription start sites and associated
CpG islands. The basis for this trend is unknown. It may be that
preintegration complexes normally associated with LEDGF/p75
become free to integrate near these sites once LEDGF/p75 was
removed. Possibly chromatin at start site regions is particularly
accessible and so represents a default target. It is also possible that
a more active mechanism is involved. In support of this idea is the
finding that MLV integration is strongly favored at start sites
[28,57], while several other integrating elements show near
random distributions [22,55,58], suggesting that mechanisms exist
to guide preferential integration near start sites. A variety of
genomic features showed positive correlation with lentiviral
integration in both the depleted cells and controls, indicating that
cellular systems in addition to LEDGF/p75 also influence
integration. As increasingly deep annotation of the human genome
accumulates, it may be possible to detect additional associations
between lentiviral integration and particular bound proteins,
potentially allowing identification of host cell factors operating in
the absence of LEDGF/p75.
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PLoS ONE | www.plosone.org 10 December 2007 | Issue 12 | e1340Finally, data presented here and in [37,41] emphasizes that
LEDGF/p75 is important for efficient HIV replication, suggesting
that the interaction between IN and LEDGF/p75 may be a
tractable target for antiviral therapy. The structure of a complex of
the LEDGF/p75 IBD and the IN catalytic domain have been
solved by X-ray crystallography[33], and the interaction surface
was found to overlap with the binding site seen previously for the
integrase inhibitor tetraphenylarsonium [59]. This supports the
idea that small molecule inhibitors, if of high enough affinity, may
be able to disrupt binding of LEDGF/p75 to integrase and so
abrogate HIV replication.
MATERIALS AND METHODS
Cell lines
MEFs were extracted from wild-type and knockout embryos at
13.5 dpc [60] and cultured in DMEM with 10% FBS, 50 mg/ml
gentamycin, 110 mM beta-mercaptoethanol, 16 non-essential
amino acids, 100 mM sodium pyruvate. Primary MEFs (prMEFs)
were immortalized by the 3T3 protocol, by splitting cells every 3
days to a density of 6610
4 cells/ml [61].
TC2 and TL2 are control (‘‘scramble’’ sequence) and active
shRNA-expressing SupT1 cell lines derived in parallel by intensified
RNAi. They wereestablished simultaneouslyfromthe sameparental
population, using equivalent MOI transduction with lentiviral
vectors that differed only in the 19 nt of the shRNA [37].
Viral particle production and infections
VSV-G pseudotyped HIV vector particles were produced by
Lipofectamine transfection of 293T cells with p156RRLsin-
PPTCMVGFPWPRE [62], the packaging construct pCMVdel-
taR9 [63], and the vesicular stomatitis virus G-producing pMD.G
construct. EIAV vector particles were likewise produced by
transfection with p6.1G3CeGFPw (M. Patel and J. Olsen,
University of North Carolina, Chapel Hill unpublished), the
packaging construct pEV53B [64], and the vesicular stomatitis
virus G-producing plasmid pVSVG into 293T cells. Viral
supernatant was harvested 38 hours after transfection, filtered
through 0.22 mm filters, concentrated by filtration through a
Centricon, treated with DNase I, and stored frozen at 280uC.
HIV titer was quantified by p24 ELISA.
For EIAV infection of SupT1 cells, cells were plated at 1610
5
cells per well of a 24-well plate, infected with between 25–100 ml
concentrated DNase I treated virus stock, and all wells were
brought to 200 ml final volume with fresh RPMI containing 10%
heat-inactivated FBS, 10 units/ml penicillin, 10 mg/ml strepto-
mycin and 50 mg/ml gentamycin (R-10). At 5 hours all well
contents were transferred to a 1.5 ml Eppendorf and spun for
10 min at 1000RPMs to pellet cells. Cells were resuspended in
1 ml R-10 and cultured for an additional 76 hrs for integration site
cloning or 2 weeks for QPCR analysis. Upon collection, 30–50%
of cells expressed GFP as analyzed by fluorescence microscopy.
For HIV infection of MEFs, cells were plated onto 6-well plates
at a density of 3610
5 cells per well and each well infected with
1 mg p24. For EIAV, cells were plated into 24-well plates at a
density of 4610
4 cells per well, and each well infected with 100 ml
concentrated virus. Infections were performed overnight in the
presence of 10 mg/ml DEAE-dextran. 10 independent HIV
infections and 5 EIAV infections were performed per genotype.
48 hours after infection, 90% of cells were harvested for
integration site cloning and the remainder passaged for an
additional 2 weeks to dilute unintegrated products of reverse
transcription and used for QPCR analysis of integration efficiency.
Infectivity tests
For quantitative PCR analysis, infected cells were passaged for 2
weeks following infection to dilute unintegrated products of reverse
transcription, then genomic DNA was extracted using the Qiagen
DNeasy tissue extraction kit. QPCR using HIV late-RT primers
and probe was carried out as described in [44] using 50 ng
genomic DNA as template. For EIAV, primer and probe
sequences are described in Table S1. 25 ng of SupT1 genomic
DNA was used as template, 50 ng of MEF genomic DNA. QPCR
was performed using Applied Biosystems 26 FAST universal
master mix and Applied Biosystems FAST PCR machine.
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Figure 9. Correlation between LEDGF/p75 expression and the frequency of HIV integration in genes. Data is shown for 15 HIV integration site
data sets in 10 cell types. The y-axis shows the percentage of integration events within transcription units of the ‘‘known gene’’ set of human genes
for each integration site data set. The x-axis shows relative expression values for LEDGF/p75 derived from Affymetrix array data (see methods for
details). The R-squared value for the fit is 0.6148 (P,0.0001). The references for the data sets used are as follows: Macrophage 1 is the VSV-G set in
[25]; Macrophage 2 is the CCR5 set in [25]; SupT1 [21]; IMR90 1 is the dividing set in [66]; IMR90 2 is the growth-arrested set in [66]; CD4 T [67]; PBMC
[22]; Jurkat 1 is the Mse set in [46]; Jurkat 2 is the Avr set in [46]; Jurkat 3 is the initially bright set in [5]; Jurkat 4 is the initially dark set in [5]; Jurkat p75
knockdown [40][46]; 293T [40]; 293T Scram [40]; 293T p75 knockdown [40].
doi:10.1371/journal.pone.0001340.g009
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PLoS ONE | www.plosone.org 11 December 2007 | Issue 12 | e1340For luciferase assays, HIV luciferase reporter virus stock was
prepared by transfection of pLai3_envLuc2 [65] and the vesicular
stomatitis virus G-producing plasmid pVSVG into 293T cells.
Viral supernatant was collected 36 h after transfection, filtered
through 0.22-mm filters, concentrated, assayed by p24 and stored
frozen at –80uC. For infectivity assay, SupT1 cells plated at 1610
5
cells per well of a 24-well plate were infected with various amounts
of concentrated DNase treated virus stock. All wells were brought
to 1 ml final volume with fresh R-10. Three days later, cells were
lysed in 0.5% Triton-X 100 in PBS and luciferase levels were
determined using Luciferase Assay System and a Thermo
Luminoskan Ascent luminescence counter. All infections were
performed in triplicate.
Integration site cloning
Integration sites were isolated and sequenced by linker-mediated
PCR essentially as described previously [46]. Genomic DNA was
extracted from infected cells using the Qiagen DNeasy tissue
extraction kit. Up to 2 mg of DNA from each infection was
digested overnight using MseI. This was followed by digestion to
prevent amplification of internal viral fragments (from the 59 LTR)
and plasmid backbone with SacI and DpnI in the case on HIV,
and XmaI and DpnI in the case of EIAV. Linkers were then
ligated onto digestion products (oligonucleotide sequences can be
found in Table S1) and nested PCR performed from ligation
products. Nested PCR primers contained 4 or 8 nt barcode
sequences between the sequencing primer and LTR-binding
portions. These enabled pooling of all PCR products into one
sequencing reaction and subsequent separation of sequences by
decoding the barcodes. Amplification products were gel-purified
and sent to the Interdisciplinary Center for Biotechnology
Research at the University of Florida and the Virginia Bioinfor-
matics Institute Core Laboratory Facility for pyrosequencing.
Bioinformatic analysis
Integration sites were judged to be authentic if the sequences had a
best unique hit when aligned to the murine or human genome as
appropriate (mm8 and hg18 respectively) using BLAT, and the
alignment began within 3bp of the viral LTR end and had .98%
sequence identity. Detailed statistical methods are described in
[55] and Statistical Reports S1 and S2.
To control for possible biases in isolating integration sites due to
restriction enzyme sequence distribution, three-ten matched
random controls were computationally generated for each
experimental integration site that were the same distance from
the closest MseI restriction site as the experimental site.
Integration site counts in various genomic annotations were
compared with matched random controls by the Fisher’s exact
test. Additionally, multiple regression models for integration
intensity were applied, as described in [55].
For analysis of correlations with gene activity in murine
integration sites (Figure 7 and 8), transcriptional profiling data
from wild-type MEFs analyzed on the MGU74Av2 Affymetrix
microarray were used. Genes represented on the microarray were
ranked by expression level and divided into 4 bins based on
expression level. Integration sites found within genes in each bin
were counted as a proportion of sites found within genes in all
bins. For human expression analysis (Figure 4) data was from [5].
For the analysis of relative gene activity in Figure 9, data from
two types Affymetrix chips were used (HU95A and HU133A).
Two probe sets querying LEDGF/p75 but not p52 were available
on each chip (For HU95: 39243_s_at and 37622_r_at; for HU133:
209337_at and 205961_s_at). To account for differences in the
sensitivities arising from the different chip designs and probe sets,
the values for each cell type were first ranked for each probe set
and chip combination, then the ranked values pooled in the final
data set.
SUPPORTING INFORMATION
Table S1 Oligonucleotides used in this study
Found at: doi:10.1371/journal.pone.0001340.s001 (0.01 MB
XLS)
Statistical Report S1 EIAV integration in human cells
Found at: doi:10.1371/journal.pone.0001340.s002 (0.35 MB
PDF)
Statistical Report S2 EIAV and HIV integration in murine
cells
Found at: doi:10.1371/journal.pone.0001340.s003 (1.44 MB
PDF)
ACKNOWLEDGMENTS
We thank members of the Bickmore, Bushman, and Poeschla laboratory
for materials and helpful discussions. We particularly thank Dr. Roderick
Jensen and members of the Virginia Bioinformatics Institute Core
Laboratory Facility for sequencing support. We also thank John C. Olsen
and Manij Patel, at the Cystic Fibrosis/Pulmonary Research and
Treatment Center, University of North Carolina at Chapel Hill for the
development and donation of the EIAV vectors, maps and infection advice.
Author Contributions
Conceived and designed the experiments: FB. Performed the experiments:
HM KR. Analyzed the data: FB HM KR. Contributed reagents/
materials/analysis tools: WB FB CB ML HS DS EP. Wrote the paper:
FB HM KR.
REFERENCES
1. Coffin JM, Hughes SH, Varmus HE (1997) Retroviruses. Cold Spring Harbor:
Cold Spring Harbor Laboratory Press.
2. Bushman FD (2001) Lateral DNA transfer: Mechanisms and consequences.
Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
3. Jordan A, Defechereux P, Verdin E (2001) The site of HIV-1 integration in the
human genome determines basal transcriptional activity and response to tat
transactivation. EMBO J 20: 1726–1738.
4. Jordan A, Bisgrove D, Verdin E (2003) HIV reporducibly establishes a
latent infection after acute infection of T cells in vitro. EMBO J 22:
1868–1877.
5. Lewinski M, Bisgrove D, Shinn P, Chen H, Verdin E, et al. (2005) Genome-wide
analysis of chromosomal features repressing HIV transcription. J Virol 79:
6610–6619.
6. Bisgrove D, Lewinski M, Bushman FD, Verdin E (2005) Molecular
mechanisms of HIV-1 proviral latency. Expert Rev Anti Infect Ther 3:
805–814.
7. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, et al.
(2003) A serious adverse event after successful gene therapy for X-linked severe
combined immunodeficiency. N Engl J Med 348: 255–256.
8. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N,
et al. (2003) LMO2-associated clonal T cell proliferation in two patients after
gene therapy for SCID-X1. Science 302: 415–419.
9. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, et al. (2003)
HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein
in human cells. J Biol Chem 278: 372–381.
10. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, et al.
(2003) LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1
integrase in human cells. J Biol Chem 278: 33528–33539.
11. Turlure F, Devroe E, Silver PA, Engelman A (2004) Human cell proteins and
human immunodeficiency virus DNA integration. Front Biosci 9: 3187–3208.
12. Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, et al. (2004) LEDGF/p75
determines cellular trafficking of diverse lentiviral but not murine oncoretroviral
LEDGF in Lentiviral Infection
PLoS ONE | www.plosone.org 12 December 2007 | Issue 12 | e1340integrase proteins and is a component of functional lentiviral preintegration
complexes. J Virol 78: 9524–9537.
13. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, et al. (2005)
Integrase mutants defective for interaction with LEDGF/p75 are impaired in
chromosome tethering and HIV-1 replication. J Biol Chem 280: 25517–23.
14. Cherepanov P, Devroe E, Silver PA, Engelman A (2004) Identification of an
evolutionarily-conserved domain of LEDGF/p75 that bind HIV-1 integrase.
J Biol Chem 279: 48883–48892.
15. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, et al. (2005)
Identification of the LEDGF/p75 HIV-1 integrase interaction domain and NLS
reveals NLS-independent chromatin tethering. J Cell Sci 118: 1733–1743.
16. Llano M, Vanegas M, Hutchins N, Thompson D, Delgado S, et al. (2006)
Identification and characterization of the chromatin-binding domains of the
HIV-1 integrase interactor LEDGF/p75. J Mol Biol 360: 760–773.
17. Turlure F, Maertens G, Rahman S, Cherepanov P, Engelman A (2006) A
tripartite DNA-binding element, comprised of the nuclear localization signal and
two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in
vivo. Nucleic Acids Res 34: 1653–1675.
18. Llano M, Delgado S, Vanegas M, Poeschla EM (2004) LEDGF/p75 prevents
proteasomal degradation of HIV-1 integrase. J Biol Chem 279: 55570–55577.
19. Busschots K, Vercammen J, Emiliani S, Benarous R, Engelborghs Y, et al.
(2005) The interaction of LEDGF/p75 with integrase is lentivirus-specific and
promotes DNA binding. J Biol Chem 280: 17841–17847.
20. Cherepanov P (2007) LEDGF/p75 interacts with divergent lentiviral integrases
and modulates their enzymatic activity in vitro. Nucleic Acids Res 35: 113–124.
21. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, et al. (2002) HIV-1
integration in the human genome favors active genes and local hotspots. Cell
110: 521–529.
22. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, et al. (2004) Retroviral
DNA integration: ASLV, HIV, and MLV show distinct target site preferences.
PLoS Biol 2: e234.
23. Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, et al. (2004) Distinct
genomic integration of MLV and SIV vectors in primate hematopoietic stem
and progenitor cells. PLoS Biol 2: e423.
24. Ciuffi A, Diamond T, Hwang Y, Marshall H, Bushman FD (2006) Fusions of
LEDGF/p75 to lambda repressor promote HIV DNA integration near lambda
operators in vitro. Human Gene Therapy 17: 960–967.
25. Barr SD, Ciuffi A, Leipzig J, Shinn P, Ecker JR, et al. (2006) HIV integration site
selection: Targeting in macrophages and the effects of different routes of viral
entry. Mol Ther 14: 218–225.
26. Barr SD, Leipzig J, Shinn P, Ecker JR, Bushman FD (2005) Integration targeting
by avian sarcoma-leukosis virus and human immunodeficiency virus in the
chicken genome. J Virol 79: 12035–12044.
27. Crise B, Li Y, Yuan C, Morcock DR, Whitby D, et al. (2005) Simian
immunodeficiency virus integration preference is similar to that of human
immunodeficiency virus type 1. J Virol 79: 12199–121204.
28. Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, et al. (2006)
Retroviral DNA integration: Viral and cellular determinants of target-site
selection. PLoS Pathog 2: e60.
29. Bushman F, Lewinski M, Ciuffi A, Barr S, Leipzig J, et al. (2005) Genome-wide
analysis of retroviral DNA integration. Nat Rev Microbiol 3: 848–858.
30. Kang Y, Moressi CJ, Scheetz TE, Xie L, Tran DT, et al. (2006) Integration site
choice of a feline immunodeficiency virus vector. J Virol 80: 8820–8823.
31. Hacker CV, Vink CA, Wardell TW, Lee S, Treasure P, et al. (2006) The
integration profile of EIAV-based vectors. Mol Ther 14: 536–545.
32. MacNeil A, Sankale JL, Meloni ST, Sarr AD, Mboup S, et al. (2006) Genomic
sites of human immunodeficiency virus type 2 (HIV-2) integration: Similarities to
HIV-1 in vitro and possible differences in vivo. J Virol 80: 7316–7321.
33. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A (2005)
Structural basis for the recognition between HIV-1 integrase and transcriptional
coactivator p75. Proc Natl Acad Sci USA 102: 17308–17313.
34. Cherepanov P, Sun ZY, Rahman S, Maertens G, Wagner G, et al. (2005)
Solution structure of the HIV integrase-binding domain in LEDGF/p75. Nat
Struct Mol Biol 12: 526–532.
35. Zielske SP, Stevenson M (2006) Modest but reproducible inhibition of human
immunodeficiency virus type 1 infection in macrophages following LEDGFp75
silencing. J Virol 80: 7275–7280.
36. Vandegraaff N, Devroe E, Turlure F, Silver PA, Engelman A (2006)
Biochemical and genetic analyses of integrase-interacting protein lens epithe-
lium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor
related protein 2 (HRP2) in preintegration complex function and HIV-1
replication. Virology 346: 415–426.
37. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W,
Poeschla EM (2006) An Essential Role for LEDGF/p75 in HIV Integration.
Science 314: 461–464.
38. Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, et al. (2006)
Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals
its role in the replication cycle of human immunodeficiency virus. J Virol 80:
1886–1896.
39. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, et al.
(2006) Overexpression of the lens epithelium-derived growth factor/p75
integrase binding domain inhibits human immunodeficiency virus replication.
J Virol 80: 11498–11509.
40. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, et al. (2005) A role for
LEDGF/p75 in targeting HIV DNA integration. Nat Med 11: 1287–1289.
41. Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, et al. (2007)
LEDGF/p75 functions downstream from preintegration complex formation to
effect gene-specific HIV-1 integration. Genes Dev 21: 1767–1778.
42. Sutherland HG, Newton K, Brownstein DG, Holmes MC, Kress C, et al. (2006)
Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal
transformations. Mol Cell Biol 26: 7201–7210.
43. Butler SL, Johnson EP, Bushman FD (2002) HIV cDNA metabolism studied by
fluorescence-monitored PCR: Notable stability of two-LTR circles. J Virol 76:
3739–3747.
44. Butler S, Hansen M, Bushman FD (2001) A quantitative assay for HIV cDNA
integration in vivo. Nat Med 7: 631–634.
45. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome
sequencing in microfabricated high-density picolitre reactors. Nature 437:
376–380.
46. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD (2007) HIV integration
site selection: Analysis by massively parallel pyrosequencing reveals association
with epigenetic modifications. Genome Res 17: 1186–1194.
47. Shoemaker DD, Lashkari DA, Morris D, Mittmann M, Davis RW (1996)
Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel
molecular bar-coding strategy. Nat Genet 14: 450–456.
48. Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, et al. (2007) DNA bar
coding and pyrosequencing to identify rare HIV drug resistance mutations.
Nucleic Acids Res 35: e91.
49. Binladen J, Gilbert MT, Bollback JP, Panitz F, Bendixen C, et al. (2007) The use
of coded PCR primers enables high-throughput sequencing of multiple homolog
amplification products by 454 parallel sequencing. PLoS ONE 2: e197.
50. Pryciak PM, Sil A, Varmus HE (1992) Retroviral integration into minichromo-
somes in vitro. EMBO J 11: 291–303.
51. Stevens SW, Griffith JD (1996) Sequence analysis of the human DNA flanking
sites of human immunodeficiency virus type 1 integration. J Virol 70:
6459–6462.
52. Carteau S, Hoffmann C, Bushman FD (1998) Chromosome structure and HIV-
1 cDNA integration: Centromeric alphoid repeats are a disfavored target. J Virol
72: 4005–4014.
53. Wu X, Li Y, Crise B, Burgess SM, Munroe DJ (2005) Weak palindromic
consensus sequences are a common feature found at the integration target sites
of many retroviruses. J Virol 79: 5211–5214.
54. Holman AG, Coffin JM (2005) Symmetrical base preferences surrounding HIV-
1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites.
Proc Natl Acad Sci USA 102: 6103–6107.
55. Berry C, Hannenhalli S, Leipzig J, Bushman FD (2006) Selection of target sites
for mobile DNA integration in the human genome. PLoS Comput Biol 2: e157.
56. Ciuffi A, Diamond TL, Hwang Y, Marshall HM, Bushman FD (2006)
Modulating target site selection during human immunodeficiency virus DNA
integration in vitro with an engineered tethering factor. Hum Gene Ther 17:
960–967.
57. Wu X, Li Y, Crise B, Burgess SM (2003) Transcription start regions in the
human genome are favored targets for MLV integration. Science 300:
1749–1751.
58. Miller DG, Trobridge GD, Petek LM, Jacobs MA, Kaul R, et al. (2005) Large-
scale analysis of adeno-associated virus vector integration sites in normal human
cells. J Virol 79: 11434–11442.
59. Molteni V, Greenwald J, Rhodes D, Hwang Y, Kwiatkowski W, et al. (2001)
Identification of a small molecule binding site at the dimer interface of the HIV
integrase catalytic domain. Acta Crystallogr D Biol Crystallogr 57: 536–544.
60. Stone M (1974) Cross-validatory chosice and assesment of statistical predictions.
Journal of the Royal Statistical Society, Series B–Methodological 36: 111–147.
61. Todaro G, Green H (1963) Quantitative studies of the growth of mouse embryo
cells in culture and their development into established lines. J Cell Biol 17:
299–313.
62. Follenzi A, Ailes LE, Bakovic S, Gueuna M, Naldini L (2000) Gene transfer by
lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol
sequences. Nat Genetics 25: 217–222.
63. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. (1996) In vivo gene
delivery and stable transduction of nondividing cells by a lentiviral vector.
Science 272: 263–267.
64. Olsen JC (1998) Gene transfer vectors derived from equine infectious anemia
virus. Gene Ther 5: 1481–1487.
65. Yamashita M, Emerman M (2004) Capsid is a dominant determinant of
retrovirus infectivity in nondividing cells. J Virol 78: 5670–5678.
66. Ciuffi A, Mitchell RS, Hoffmann C, Leipzig J, Shinn P, et al. (2006) Integration
site selection by HIV-based vectors in dividing and growth-arrested IMR-90
lung fibroblasts. Mol Ther 13: 366–373.
67. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006)
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc
Natl Acad Sci USA 103: 17372–17377.
LEDGF in Lentiviral Infection
PLoS ONE | www.plosone.org 13 December 2007 | Issue 12 | e1340